HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Seeks Label Expansion for Ezharmia into PTCL in Japan
February 1, 2024
- Keytruda/Padcev Filed in Japan for 1st Line Bladder Cancer Treatment: MSD, Astellas
February 1, 2024
- Parmodia Again Tops December GP Rep Promotion Ranking, Dayvigo 5th Month Title Holder for HP
February 1, 2024
- Axcelead DDP Looks to Lift Overseas Sales Ratio to 80%: President
January 31, 2024
- Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout
January 31, 2024
- Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
January 31, 2024
- US FDA Approves Additional CIDP Use for Takeda’s Gammagard Liquid
January 31, 2024
- Takeda’s Hyqvia Nabs European Approval for CIDP Maintenance Therapy
January 31, 2024
- Susmed Drops Reimbursement Request for Insomnia App
January 30, 2024
- Enhertu Gets FDA’s Priority Review for Pan-Tumor Indication: Daiichi Sankyo
January 30, 2024
- Astellas/Pfizer Seeks 1st Line Bladder Cancer Use for Padcev/Keytruda in EU
January 30, 2024
- Eisai Resubmits Ultra-High Dose Mecobalamin in Japan for ALS
January 29, 2024
- Mitsubishi Tanabe Newly Pledges 100 Billion Yen for GHIT Fund
January 29, 2024
- Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
January 29, 2024
- Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
- Shionogi Partners with Niremia Collective to Fund Well-Being Tech Startups
January 26, 2024
- BlueRock In-Licenses Fujifilm’s iPSC Therapy for Ocular Disease
January 25, 2024
- Kyowa Kirin Closes Acquisition of UK Gene Therapy Player Orchard
January 25, 2024
- Takeda’s Cuvitru Now Available in Japan as Its First SC Immunoglobulin
January 25, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
